Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

This is the foundational human pharmacokinetic and pharmacodynamic study of CJC-1295 with DAC and the basis for every claim about the molecule's unique long-duration profile. The trial design comprised two randomized, placebo-controlled, double-blind ascending-dose studies of 28 and 49 days in healthy adult volunteers (ages 21 to 61). The headline pharmacokinetic finding is the plasma half-life of 5.8 to 8.1 days — orders of magnitude longer than native GHRH or any GHRH analog without the DAC tether. Pharmacodynamically, a single subcutaneous injection produced dose-dependent increases in plasma GH of 2- to 10-fold sustained for six days or longer, and IGF-1 increases of 1.5- to 3-fold lasting nine to eleven days. With multiple doses, IGF-1 stayed above baseline for up to 28 days, indicating that weekly or twice-weekly dosing is sufficient to maintain a sustained IGF-1 elevation. No serious adverse reactions were reported during the published trial. The authors framed CJC-1295 as a candidate therapeutic for indications currently treated with daily GH replacement, where the dosing-frequency reduction is clinically meaningful.

Sample sizes in the dose-escalation cohorts are small relative to a Phase II or III program, which limits the power to detect uncommon adverse events. The trial was conducted in healthy adults aged 21 to 61, not the older or comorbid populations that would drive a therapeutic indication; generalizability is not established. The published paper does not address the chronic-IGF-1-elevation safety question that applies to anyone using CJC-1295 with DAC for months to years rather than weeks to a few months. The original sponsor program encountered a serious safety event in a hypertension subindication trial that is not addressed in this paper; readers should treat the safety data here as Phase I in scope, not as the totality of what is known about the molecule. Industry sponsorship by ConjuChem (the original developer) is disclosed.